证券代码：002252 证券简称：上海莱士 公告编号：2025-070 上海莱士血液制品股份有限公司 关于股份回购完成暨回购实施结果的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）于 2025 年 1 月 13 日召开了第六 届董事会第七次（临时）会议，审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有或自筹资金以集中竞价交易方式从二级市场回购公司股份，用 于实施员工持股计划或股权激励，拟回购股份的资金总额为不低于人民币 2.5 亿 元（含）且不超过人民币 5 亿元（含），拟回购股份价格不超过人民币 9.55 元/ 股（含），具体回购股份数量以回购股份方案实施完毕或回购实施期限届满时实 际回购情况为准。回购期限自股东大会审议通过本次回购股份方案之日起 12 个 月内，如果触及回购股份方案提及的相关条件时，回购期限提前届满。公司于 2025 年 2 月 14 日召开 2025 年第一次临时股东大会审议通过了上述股份回购方 案。具体内容详见公司分别于 2025 年 1 月 14 日、2025 年 2 月 1 ...

Core Viewpoint - The company has announced its profit distribution plan for the first three quarters of 2025, aiming to enhance shareholder returns while ensuring sufficient liquidity for operations and growth [20][21][24]. Financial Data - For the first nine months of 2025, the company reported a net profit attributable to shareholders of 1,470,738,960.56 yuan, with the parent company achieving a net profit of 953,611,770.21 yuan [21][24]. - The total distributable profit as of September 30, 2025, is 11,175,120,755.02 yuan, after accounting for previously paid cash dividends of 217,371,383.70 yuan [21][24]. Profit Distribution Plan - The proposed distribution plan suggests a cash dividend of 0.153 yuan per share (including tax) for every 10 shares held, which is expected to total approximately 100,515,842.14 yuan [21][22][24]. - The plan will be implemented within two months after approval at the shareholders' meeting, with adjustments made if the total share capital changes before the distribution [22][24]. Shareholder Engagement - The company emphasizes its commitment to enhancing shareholder returns and maintaining a long-term investment perspective, aligning with its operational and strategic goals [24][25]. - The board and supervisory committee have reviewed and approved the profit distribution plan, ensuring compliance with relevant regulations [26][27][41]. Clinical Trials and Product Development - The company is advancing its clinical trials for the SR604 injection, which has received regulatory approval for various phases, indicating ongoing investment in product development [14][17][18]. - The SR604 injection aims to address bleeding prevention in patients with hemophilia and has recently applied for additional indications [17][18]. Employee Stock Ownership Plan - The company has approved the unlocking of shares under its first employee stock ownership plan, reflecting its strategy to align employee interests with company performance [50][54]. - The plan's conditions have been met for a significant number of participants, indicating a successful implementation of the employee incentive strategy [50][54]. Strategic Direction - The company is focused on becoming a leading biopharmaceutical enterprise through innovation and strategic acquisitions, aiming for sustainable growth in the blood products industry [24][25]. - The dual strategy of internal growth and external acquisitions is designed to enhance operational capabilities and market position [24].

证券代码：002252 证券简称：上海莱士 公告编号：2025-066 上海莱士血液制品股份有限公司 关于第六届监事会第九次会议决议的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）第六届监事会第九次会议于 2025 年 10 月 18 日以电子邮件方式发出通知，并于 2025 年 10 月 24 日下午 5 点以现 场结合通讯方式召开。 会议应出席监事 3 名，实际出席监事 3 名。本次会议由监事会主席张吉女士 召集和主持。会议的召集召开与表决程序符合《公司法》和《公司章程》等有关 规定。与会监事经过充分研究和讨论，审议并通过了如下议案： 1、审议通过《2025 年第三季度报告》 经审核，监事会认为：董事会编制和审核公司《2025 年第三季度报告》的 程序符合法律、行政法规和中国证券监督管理委员会的规定，报告内容真实、准 确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者 重大遗漏。 表决结果：3 票同意，0 票弃权，0 票反对。 《2025 年第三季度报告》刊登于《证券时报》、《中国证券报》 ...

证券代码：002252 证券简称：上海莱士 公告编号：2025-068 一、利润分配预案的基本情况 （一）本次利润分配预案的基本内容 1、分配基准：2025年三季度 2 、 公 司 2025 年 度 1~9 月 合 并 报 表 实 现 归 属 于 母 公 司 所 有 者 净 利 润 1,470,738,960.56元（其中：母公司实现净利润为953,611,770.21元），加上年初未 分配利润9,921,753,178.16元（其中：母公司年初未分配利润4,682,303,602.44元）， 减去2025年度已支付现金股利217,371,383.70元，截至2025年9月30日，公司合并 报表累计可供股东分配的利润为11,175,120,755.02元（其中：母公司报表实际可 供股东分配的利润为5,418,543,988.95元）。（以上前三季度财务数据未经审计） 3、根据中国证监会《上市公司监管指引第3号——上市公司现金分红》及《公 司章程》《公司未来三年(2024—2026年)股东回报规划》等相关规定，综合考虑 公司实际经营情况及对公司股东的回报等因素，公司2025年度1~9月利润分配预 案为：拟以分红 ...

Financial Performance - The company's revenue for Q3 2025 was ¥2,138,864,925.93, representing a 3.72% increase year-over-year, while the year-to-date revenue decreased by 3.54% to ¥6,091,056,594.53[4] - Net profit attributable to shareholders for Q3 2025 was ¥440,846,798.50, a decrease of 26.16% compared to the same period last year, with a year-to-date net profit decline of 19.97% to ¥1,470,738,960.56[4] - The basic earnings per share for Q3 2025 was ¥0.067, down 25.56% year-over-year, and the diluted earnings per share also decreased by the same percentage[4] - The company reported total operating revenue of ¥6,091,056,594.53 for the current period, a decrease of 3.5% compared to ¥6,314,412,912.62 in the previous period[33] - The company's net profit from investments was ¥269,299,096.88, down from ¥439,917,036.98 in the previous period, reflecting a decline of approximately 38.8%[33] - The net profit for the current period is CNY 1,470,320,036.30, a decrease of 19.99% compared to CNY 1,838,514,042.16 in the previous period[34] - The total comprehensive income for the current period is CNY 1,365,506,628.54, down from CNY 1,685,104,868.09 in the previous period, reflecting a decline of 18.93%[35] - Basic and diluted earnings per share are both CNY 0.222, compared to CNY 0.277 in the previous period, indicating a decrease of 20%[35] - The company's operating profit decreased to CNY 1,744,204,358.95 from CNY 2,261,253,944.01, reflecting a decline of 22.83%[34] Assets and Liabilities - Total assets at the end of Q3 2025 reached ¥38,020,411,474.40, reflecting a 13.05% increase from the end of the previous year[4] - Total assets increased to ¥38,020,411,474.40 from ¥33,631,225,254.06, reflecting a growth of about 13.1%[31] - Total liabilities rose to ¥5,436,804,293.46 from ¥1,690,505,789.91, showing a significant increase, primarily due to long-term borrowings[30] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥690,903,086.19, an increase of 33.99% compared to the previous year[8] - Cash flow from operating activities generated a net amount of CNY 690,903,086.19, an increase of 33.94% from CNY 515,627,395.21 in the previous period[37] - Cash flow from investing activities resulted in a net outflow of CNY 2,671,044,847.28, worsening from a net outflow of CNY 1,113,733,825.29 in the previous period[37] - Cash flow from financing activities generated a net inflow of CNY 1,773,832,354.42, compared to a net outflow of CNY 453,980,207.07 in the previous period, showing a significant improvement[37] - Cash and cash equivalents decreased to ¥2,096,006,316.90 from ¥2,982,705,503.57, representing a decline of approximately 29.7%[28] - The total cash and cash equivalents at the end of the period is CNY 1,129,621,936.26, down from CNY 2,142,061,370.80 at the end of the previous period[37] Shareholder Information - As of September 30, 2025, Haiyingkang (Qingdao) Medical Technology Co., Ltd. holds 1,547,513,352 shares, representing 23.31% of the total share capital[11] - Grifols, S.A. retains 437,069,656 shares, accounting for 6.58% of the total share capital[11] - The total number of shares repurchased by the company as of September 30, 2025, is 68,321,952 shares, which is 1.03% of the total share capital[13] - The total amount spent on share repurchases by the company is approximately RMB 469.85 million[13] - The maximum repurchase price per share is capped at RMB 9.55, with the highest transaction price recorded at RMB 7.09 and the lowest at RMB 6.62[13][14] - Haiyingkang and Grifols, S.A. have formed a concerted action relationship, controlling a combined total of 1,984,583,008 shares, or 29.90% of the total share capital[11] - The top ten shareholders collectively hold significant stakes, with the largest shareholder owning 23.31% of the total shares[11] - The controlling shareholder, Haiyingkang, increased its stake by 72,439,700 shares, representing 1.09% of the total share capital, with a total investment of approximately RMB 496.83 million during the first buyback plan[15] - In the second buyback plan, Haiyingkang acquired 73,042,200 shares, accounting for 1.10% of the total share capital, with a total investment of about RMB 499.86 million[17] - The third buyback plan saw Haiyingkang purchase 72,935,300 shares, also representing 1.10% of the total share capital, with a total investment of approximately RMB 499.99 million[18] - The company plans to use between RMB 250 million and RMB 500 million for share repurchase purposes[12] - The share repurchase program is intended for employee stock ownership plans or equity incentives[12] - The share repurchase lock-up period for Haiyingkang and Grifols, S.A. is set for 36 months following the completion of the transaction[11] Clinical Trials and Product Development - The company received approval for the clinical trial of "SR604 Injection" for hemophilia treatment, with the first phase starting in March 2024[20] - "SR604 Injection" entered the second phase of clinical trials, focusing on safety, tolerability, and effectiveness in hemophilia patients[21] - The company has applied for an additional clinical trial indication for "SR604 Injection" to prevent bleeding in patients with von Willebrand disease, which has been accepted by the regulatory authority[22] - The company has initiated clinical trials for SR604 injection for the prevention of bleeding in patients with von Willebrand disease, with a new application submitted to the National Medical Products Administration[24] - The company has entered the phase IIb trial stage for SR604 injection, having received preliminary safety and efficacy data[24] Asset and Credit Impairment - The company reported a significant increase in accounts receivable, which rose by 63.64% to ¥2,288,582,185.54 due to adjustments in sales credit policies[7] - Accounts receivable increased significantly to ¥2,288,582,185.54 from ¥1,398,534,714.31, marking a rise of about 63.7%[28] - The company reported a credit impairment loss of CNY -43,562,114.27, compared to CNY -32,094,300.41 in the previous period, indicating an increase in credit losses[34] - The company experienced an asset impairment loss of CNY -44,325,502.36, significantly higher than CNY -13,506,413.52 in the previous period[34]

证券代码：002252 证券简称：上海莱士 公告编号：2025-069 上海莱士血液制品股份有限公司关于 第一期员工持股计划锁定期届满暨解锁条件成就的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）于 2025 年 10 月 24 日召开第六 届董事会第十四次（临时）会议，审议通过了《关于第一期员工持股计划锁定期 届满暨解锁条件成就的议案》，董事会认为公司第一期员工持股计划本次锁定期 解锁条件已成就。根据《关于上市公司实施员工持股计划试点的指导意见》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》《公司 第一期员工持股计划》等相关规定，现将情况公告如下： 一、第一期员工持股计划的基本情况 公司于 2023 年 7 月 28 日分别召开了第五届董事会第二十六次（临时）会议 和第五届监事会第十九次会议，审议并通过了《关于<上海莱士血液制品股份有 限公司第一期员工持股计划（草案）>及其摘要的议案》、《关于<上海莱士血液 制品股份有限公司第一期员工持股计划管理办法>的议案》等相关议案，同意公 司实 ...

上海莱士血液制品股份有限公司 关于第六届董事会第十四次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）第六届董事会第十四次（临时） 会议于 2025 年 10 月 18 日以邮件方式发出会议通知，并于 2025 年 10 月 24 日下 午 4 点以现场结合通讯方式召开。 本次会议应出席董事 9 名，亲自出席董事 8 名。董事 Amarant Martínez Carrió 先生因行程冲突未能亲自出席本次会议，委托董事王全立先生出席并行使表决权。 本次会议由公司董事长谭丽霞女士召集和主持，公司监事、高级管理人员等列席 会议。会议的召集、召开与表决程序符合《公司法》和《公司章程》等有关规定。 与会董事经过充分研究和讨论，审议通过了如下议案： 证券代码：002252 证券简称：上海莱士 公告编号：2025-065 除上述现金分红外，本次利润分配公司不送红股，不以公积金转增股本。 1、审议通过《2025 年第三季度报告》 表决结果：9票同意、0票反对、0票弃权。 本议案已经公司第六届董事会审计委员会审议通 ...

Core Viewpoint - The company emphasizes the importance of reasonable investment returns for all shareholders while balancing its development plans and financial status in its dividend policy [1] Group 1 - The company is currently focused on reserving strategic funds to support the future "deproteinization strategy," which is crucial for its strategic transformation [1] - The company aims to lay a solid foundation for long-term development through this strategic transition [1] - Future dividend policies will be planned reasonably, taking into account the balance between company growth and shareholder returns [1]

Core Viewpoint - The company is currently in the trial production phase at its Guangxi facility and aims to gradually increase production capacity after completing trial production and drug registration approval [2]. Group 1: Company Operations - Guangxi facility is in trial production stage and will enhance output once trial production and drug registration are completed [2]. - The company emphasizes that the blood products industry has unique characteristics, with production capacity primarily influenced by plasma collection capabilities and regulatory approvals [2]. - The company is committed to expediting the approval process for Guangxi products to achieve stable operations [2].

Core Insights - The Biotech Economy Index (970038) closed at 2261.4 points, down 0.81%, with a trading volume of 16.635 billion yuan and a turnover rate of 1.19% [1] - Among the index constituents, 19 stocks rose while 30 stocks fell, with Meihao Medical leading the gainers at 6.53% and Prolo Pharma leading the decliners at 5.41% [1] Index Performance - The Biotech Economy Index experienced a decline of 0.81% on the reporting day [1] - The total market capitalization of the index constituents was significant, with major players like Mindray Medical valued at 266.98 billion yuan [1] Top Constituents - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (13.81% weight, 220.20 yuan, -1.51% change, 2669.80 billion yuan market cap) [1] - Changchun High-tech (5.41% weight, 119.11 yuan, -0.97% change, 485.89 billion yuan market cap) [1] - Kanglong Chemical (4.66% weight, 30.96 yuan, +0.29% change, 550.53 billion yuan market cap) [1] - Other notable constituents include Taige Pharmaceutical, Muyuans, and Aimeike, all within the biotech and healthcare sectors [1] Capital Flow - The net outflow of main funds from the Biotech Economy Index constituents totaled 0.893 billion yuan, while retail investors saw a net inflow of 0.75 billion yuan [1] - Specific stocks like Kanglong Chemical and Meihao Medical experienced varying levels of net inflow and outflow from different investor categories [2]